Clearside Biomedical Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Clearside Biomedical stock.
View analyst ratings for Clearside Biomedical or view top-rated stocks.

Wall Street analysts have given Clearside Biomedical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Clearside Biomedical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Clearside Biomedical saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 515,600 shares, an increase of 29.1% from the January 28th total of 399,400 shares. Based on an average daily volume of 853,800 shares, the short-interest ratio is presently 0.6 days.
View Clearside Biomedical's Short Interest.

Clearside Biomedical is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for Clearside Biomedical.

Clearside Biomedical will be holding an earnings conference call on Wednesday, March 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Clearside Biomedical, Inc. (NASDAQ:CLSD) released its earnings results on Sunday, November, 15th. The company reported ($0.05) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.12) by $0.07. The business earned $3.43 million during the quarter, compared to analysts' expectations of $0.70 million. Clearside Biomedical had a negative net margin of 144.47% and a negative trailing twelve-month return on equity of 153.41%.
View Clearside Biomedical's earnings history.

Clearside Biomedical's stock was trading at $2.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CLSD stock has increased by 27.8% and is now trading at $3.31.
View which stocks have been most impacted by COVID-19.

4 analysts have issued 1-year price targets for Clearside Biomedical's shares. Their forecasts range from $5.00 to $8.00. On average, they anticipate Clearside Biomedical's share price to reach $6.33 in the next twelve months. This suggests a possible upside of 91.3% from the stock's current price.
View analysts' price targets for Clearside Biomedical or view top-rated stocks among Wall Street analysts.

Some companies that are related to Clearside Biomedical include Atreca (BCEL), Basilea Pharmaceutica (BPMUF), Chimerix (CMRX), BELLUS Health (BLUSF), KalVista Pharmaceuticals (KALV), Foghorn Therapeutics (FHTX), Ardelyx (ARDX), Eagle Pharmaceuticals (EGRX), Evelo Biosciences (EVLO), Inventiva (IVA), Summit Therapeutics (SMMT), XBiotech (XBIT), Geron (GERN), IDEAYA Biosciences (IDYA) and Applied Therapeutics (APLT).
View all of CLSD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Melinta Therapeutics (MLNT), OrganiGram (OGI), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Miragen Therapeutics (MGEN) and Gran Tierra Energy (GTE).

(CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

Clearside Biomedical's stock is owned by many different retail and institutional investors. Top institutional shareholders include Acuta Capital Partners LLC (2.59%), BlackRock Inc. (1.58%), Renaissance Technologies LLC (0.95%), GSA Capital Partners LLP (0.12%), Signaturefd LLC (0.11%) and Synovus Financial Corp (0.06%). Company insiders that own Clearside Biomedical stock include Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, Nancy J Hutson and William D Humphries.
View institutional ownership trends for Clearside Biomedical.

CLSD stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Signaturefd LLC. Company insiders that have sold Clearside Biomedical company stock in the last year include Clay Thorp, and George M Lasezkay.
View insider buying and selling activity for Clearside Biomedical or view top insider-selling stocks.

CLSD stock was purchased by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, Synovus Financial Corp, Trustcore Financial Services LLC, BlackRock Inc., Cambridge Investment Research Advisors Inc., and GSA Capital Partners LLP. Company insiders that have bought Clearside Biomedical stock in the last two years include Bradford T Whitmore, Charles A Deignan, George M Lasezkay, Nancy J Hutson, and William D Humphries.
View insider buying and selling activity for Clearside Biomedical or or view top insider-buying stocks.

Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLSD stock can currently be purchased for approximately $3.31.

Clearside Biomedical has a market capitalization of $160.05 million and generates $2.17 million in revenue each year. The company earns $-30,770,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis.

Clearside Biomedical employs 33 workers across the globe.

The official website for Clearside Biomedical is www.clearsidebio.com.

Clearside Biomedical is headquartered at 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005.

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]